Today's Hours: 8:00am - 10:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    Muhammad Zia-Ul-Haq, May Nasser Bin-Jumah, Sarah I. Alothman, Hanan A. Henidi, editors.
    Summary: This research volume examines the available alternative, complementary, pharmaceutical and vaccine methods for treating, mitigating, or preventing COVID-19. Coverage includes traditional Chinese medicine, herbal remedies, nutraceutical/dietary options, and drug/vaccine therapies. All the methods discussed will be critically examined to provide readers with a full, unbiased overview that includes pros/cons of each method. While the nature of COVID-19 is still being studied, and new research and theories are being published daily, this book endeavors to provide readers with a comprehensive summary of current research on alternative and mainstream treatment and prevention methods.

    Contents:
    Intro
    Preface
    Contents
    About the Editors
    Chapter 1: Introduction to COVID-19
    Introduction
    Origin of COVID
    Emergence and Epidemiology
    Human-Animal Interaction as Risk Factor
    Best Suitable Animal Model
    COVID and Animal Welfare
    Molecular Differences Between Different Animal Species
    Vaccines for COVID from Animals
    Conclusion
    References
    Chapter 2: Medicinal Plants as COVID-19 Remedy
    Introduction
    Existing Plants with Potential Therapeutic Applications for Coronavirus Family (SARS-CoV)
    Plants as Specific Inhibitors of HCoV Target Proteins Bupleurum Species
    Artemisia annua L.
    Isatis indigotica Fortune ex Lindl.
    Alcea digitata (Boiss.) Alef.
    Lycoris radiata (L'Hér.) Herb.
    Pyrrosia lingua (Thunb.) Farw.
    Houttuynia cordata Thunb.
    Torreya nucifera L.
    Lindera aggregata (Sims) Kosterm.
    Rheum palmatum L.
    Cerasus avium (L.) Moench.
    Polygonum multiflorum Thunb.
    Citrus aurantium L.
    Rubia tinctorum L.
    Onopordum acanthium L.
    Quercus infectoria G. Olivier
    Crataegus microphylla C. Koch
    Berberis integerrima Bunge
    Alnus japonica (Thunb.) Steud.
    Paulownia tomentosa (Thunb.) Steud. Psoralea corylifolia L.
    Tribulus terrestris L.
    Medicinal Plants as Potential Source of Natural Antiviral Agents Against COVID -19
    Allium Sativum (Garlic)
    Azadirachta indica (Neem)
    Curcuma domestica (Turmeric, Haldi)
    Echinacea purpurea L. (Echinacea)
    Foeniculum vulgare Mill. (Fennel)
    Glycyrrhiza glabra (Licorice)
    Melissa officinalis L. (Lemon Balm)
    Mentha piperita L. (Peppermint)
    Nigella sativa L. (Black Seeds)
    Origanum vulgare L. (Oregano)
    Ocimum bacilicum L. (Basil)
    Rosmarinus officinalis L. (Rosemary)
    Salvia officinalis L. (Sage) Senna alexandrina Mill. (Senna Makki)
    Zingiber officinale Rosc. (Ginger)
    Limitations
    Conclusions
    References
    Chapter 3: Traditional Chinese Medicines as Possible Remedy Against SARS-CoV-2
    Introduction
    Traditional Chinese Medical Practices
    Laws for TCM Formulation
    Antiviral Potential of Plant Metabolites
    Structure of SARS-CoV-2
    Relevance of SARS-CoV with SARS-CoV-2
    Entry of SARS-CoV vs. SARS-CoV-2 into Host Cell
    TCM and SARS-CoV
    TCM and SARS-CoV-2 (COVID-19)
    Most Practiced Herbs in Formulations Against COVID-19 Utilization Frequency of Herbs in the Formulation of (COVID-19) Decoctions
    Approved/Proposed Decoctions with Successful Clinical Trials
    Qingfei Paidu Decoction (QFPD) (Approved)
    Huashi Baidu Decoction (HBD) (Approved)
    Xiaochaihu Decoction (XCHD)
    Xuanfei Baidu Decoction (XFBD) (Approved)
    Jinhua Qinggan (JQ) (Approved)
    Huoxiang Zhengqi (HZ) Capsule
    Lianhua Qingwen (LQ)
    Xuebijing Injection (XbI) (Approved)
    Reduning Injection (RdI)
    Shufeng Jiedu Capsule (SFJC)
    Ma Xing Shi Gan Decoction (MXSGD) (Approved)
    Yin Qiao San (YQS)
    Yupingfeng San (YPFS)
    Digital Access Springer 2021
  • Article
    Paoletti P, Robustelli della Cuna G, Knerich R, Strada MR.
    Acta Neurochir (Wien). 1978;41(4):287-99.
    The authors report the results of a controlled clinical trial in patients with primitive and metastatic CNS tumours treated with combined therapy: surgery, radiotherapy, and chemotherapy (BCNU or CCNU). A total of 102 patients were treated, 50 with BCNU, and 52 with CCNU. The overall response (R. + P.R.) was 68% for the BCNU group, and 65% for the CCNU group. No significant differences were found between the two types of treatment, either in terms of response or in terms of quality and length of survival.
    Digital Access Access Options